Phase IV Trial of Miltefosine in Adults and Children for Treatment of Visceral Leishmaniasis (Kala-Azar) in Bangladesh
- 1 July 2011
- journal article
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 85 (1), 66-69
- https://doi.org/10.4269/ajtmh.2011.10-0661
Abstract
Miltefosine (target dose of 2.5 mg/kg/day for 28 days) is the recommended treatment for visceral leishmaniasis (kala-azar) in Bangladesh on the basis of data from India. We evaluated miltefosine in a phase IV trial of 977 patients in Bangladesh. At the six-month final follow up, 701 were cured. 24 showed initial treatment failure, and 95 showed treatment failure at 6 months, although 73 of the 95 showed treatment failure solely by the criterion of low hemoglobin values. One hundred twenty-one patients were not assessable. With the conservative assumption that all low hemoglobin values represented treatment failure, the final per protocol cure rate was 85%. Of 13 severe adverse events, 6 led to treatment discontinuation and 7 resulted in deaths, but only 1 death (associated with diarrhea) could be attributed to drug. Nearly all non-serious adverse events were gastrointestinal: vomiting in 25% of patients and diarrhea in 8% of patients. Oral miltefosine is an attractive alternative to intramuscular antimony and intravenous amphotericin B for treatment of kala-azar in Bangladesh.Keywords
This publication has 9 references indexed in Scilit:
- Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian SubcontinentPLoS Neglected Tropical Diseases, 2010
- Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in IndiaNew England Journal of Medicine, 2010
- Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinentTransactions of the Royal Society of Tropical Medicine and Hygiene, 2008
- Amphotericin B Treatment for Indian Visceral Leishmaniasis: Response to 15 Daily versus Alternate-Day InfusionsClinical Infectious Diseases, 2007
- Phase 4 Trial of Miltefosine for the Treatment of Indian Visceral LeishmaniasisThe Journal of Infectious Diseases, 2007
- Oral Miltefosine for Indian Visceral LeishmaniasisNew England Journal of Medicine, 2002
- Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agendaThe Lancet Infectious Diseases, 2002
- Failure of Pentavalent Antimony in Visceral Leishmaniasis in India: Report from the Center of the Indian EpidemicClinical Infectious Diseases, 2000
- Miltefosine, an Oral Agent, for the Treatment of Indian Visceral LeishmaniasisNew England Journal of Medicine, 1999